Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy
- 15 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (9), 2496-2507
- https://doi.org/10.1038/s41375-021-01160-1
Abstract
There is increasing interest in targeting CD33 in malignant and non-malignant disorders. In acute myeloid leukemia, longer survival with the CD33 antibody-drug conjugate gemtuzumab ozogamicin (GO) validates this strategy. Still, GO benefits only some patients, prompting efforts to develop more potent CD33-directed therapeutics. As one limitation, CD33 antibodies typically recognize the membrane-distal V-set domain. Using various artificial CD33 proteins, in which this domain was differentially positioned within the extracellular portion of the molecule, we tested whether targeting membrane-proximal epitopes enhances the effector functions of CD33 antibody-based therapeutics. Consistent with this idea, a CD33V-set/CD3 bispecific antibody (BsAb) and CD33V-set-directed chimeric antigen receptor (CAR)-modified T cells elicited substantially greater cytotoxicity against cells expressing a CD33 variant lacking the entire C2-set domain than cells expressing full-length CD33, whereas cytotoxic effects induced by GO were independent of the position of the V-set domain. We therefore raised murine and human antibodies against the C2-set domain of human CD33 and identified antibodies that bound CD33 regardless of the presence/absence of the V-set domain (“CD33PAN antibodies”). These antibodies internalized when bound to CD33 and, as CD33PAN/CD3 BsAb, had potent cytolytic effects against CD33+ cells. Together, our data provide the rationale for further development of CD33PAN antibody-based therapeutics.This publication has 30 references indexed in Scilit:
- The past and future of CD33 as therapeutic target in acute myeloid leukemiaBlood Reviews, 2014
- Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AMLBlood, 2014
- Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaBlood, 2013
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapyBlood, 2012
- Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectorsNucleic Acids Research, 2011
- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigenCancer Immunology, Immunotherapy, 2010
- A modular IgG-scFv bispecific antibody topologyProtein Engineering, Design and Selection, 2009
- Phosphorylated ITIMs Enable Ubiquitylation of an Inhibitory Cell Surface ReceptorTraffic, 2007
- ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2Journal of Leukocyte Biology, 2007
- Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin–induced cytotoxicityBlood, 2005